- ►diabetesjournals.org J Rosenstock, SG Shen, MR Gatlin, JE Foley - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—At the 16-week end point, nateglinide 120 mg, troglitazone 600 mg, and
the combination of the agents achieved statistically significant decreases in
HbA 1c in comparison with placebo and a baseline HbA 1c of 8.1–8.4% (P < ... Cited by 36 - Related articles - BL Direct - All 7 versions
- ►endojournals.org C Saloranta, K Hershon, M Ball, S Dickinson, … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Nateglinide is a fast-acting insulin secretion agent that specifically targets
postprandial hyperglycemia in patients with type 2 diabetes. The recent
reduction in the diagnostic criteria for diabetes and improved ... Cited by 43 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org V Fonseca, G Grunberger, S Gupta, S Shen, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In placebo-treated patients, HbA 1c did not change (Δ = 0.0 ± 0.1%).
In patients randomized to nateglinide, HbA 1c decreased from 8.3 to 7.5% (Δ =
−0.8 ± 0.1%, P < 0.0001 vs. placebo). Target HbA 1c (<7.0%) was achieved ... Cited by 35 - Related articles - BL Direct - All 9 versions
M Marre, L Van Gaal, KH Usadel, M Ball, I … - Diabetes Obesity and Metabolism, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 45 - Related articles - BL Direct - All 4 versions
ES Horton, JE Foley, SG Shen, MA Baron - Current Medical Research and Opinion®, 2004 - informahealthcare.com Objective: To assess the efficacy and tolerability of the combination of
nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in
drug-naïve patients with type 2 diabetes mellitus (T2DM). Research design ... Cited by 19 - Related articles - BL Direct - All 7 versions
- ►diabetesweb.de [PDF] - Free from Publisher PA Hollander, SL Schwartz, MR Gatlin, SJ … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—During the liquid-meal challenge, nateglinide reduced the incremental
glucose area under the curve (AUC) more effectively than glyburide (Δ = −4.94
vs. −2.71 mmol · h/l, P < 0.05), whereas glyburide reduced fasting ... Cited by 100 - Related articles - BL Direct - All 7 versions
- Free from Publisher M Hanefeld, KP Bouter, S Dickinson, C … - Diabetes Care, 2000 - Am Diabetes Assoc F rom the Outpatient Department, Institute of Clinical Metabolic Research,
Medical Faculty, Technical Uni- versity of Dresden (MH), Dresden, Germany; Bosch
Medicentre (KPB), Den Bosch, the Netherlands; and N ova rtis Pharma AG (SD, ... Cited by 147 - Related articles - BL Direct - All 7 versions
- Free from Publisher S Del Prato, RJ Heine, L Keilson, C Guitard … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Retrospective subgroup analyses were performed on
pooled data from all completed nateglinide studies (12 randomized, double blind
trials and 1 open trial) in patients with type 2 diabetes. A total of 3,702 ... Cited by 26 - Related articles - BL Direct - All 5 versions
- Free from Publisher A Mari, A Gastaldelli, JE Foley, RE Pratley, E … - Diabetes care, 2005 - Am Diabetes Assoc RESULTS—The baseline demographic and metabolic characteristics of the four
groups were similar. Nateglinide treatment resulted in dose-dependent reductions
in the mean postprandial glucose response and at the 120-mg dose in fasting ... Cited by 21 - Related articles - All 6 versions
